Prostate Cancer Imaging with 18F-Fluciclovine
- PMID: 36229104
- DOI: 10.1016/j.cpet.2022.07.005
Prostate Cancer Imaging with 18F-Fluciclovine
Abstract
18F-Fluciclovine PET is approved for the evaluation of patients with suspected prostate cancer recurrence. 18F-Fluciclovine PET is highly specific for the localization of extraprostatic disease even with negative conventional images and low prostate-specific antigen and has been reported to influence patients' management and improve outcome. With the recent Food and Drug Administration approval of prostate-specific membrane antigen (PSMA) PET, 18F-Fluciclovine is likely to be used as an adjunct modality in patients with suspected occult local recurrence and/or negative PSMA findings.
Keywords: FACBC; Fluciclovine; PET/CT; PET/MR; Prostate cancer.
Copyright © 2022 Elsevier Inc. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
